Modern approaches to the treatment of diabetes mellitus: A review. Moscow City Congress of Endocrinologists “Endocrinology of the capital – 2024”. Review of the congress on March 29–31, 2024
- Issue: Vol 26, No 4 (2024): Эндокринология
- Pages: 215-218
- Section: Articles
- URL: https://journals.rcsi.science/2075-1753/article/view/257350
- DOI: https://doi.org/10.26442/20751753.2024.4.202765
- ID: 257350
Cite item
Full Text
Abstract
The XVII Moscow City Congress of Endocrinologists, "Endocrinology of the Capital – 2024," is one of the most significant medical events in Russia's field of endocrinology. The event brings together leading domestic and international experts in endocrinology to present reports, symposia, and seminars on the latest developments in treatment and personalized therapeutic strategies. Leading Russian experts discussed recent advances in the treatment of type 2 diabetes mellitus. They analyzed the current global trends in combined drug therapy, presented new data on hypoglycemic medication safety and efficacy for pregnant women with type 2 diabetes mellitus, and discussed the significance of non-alcoholic fatty liver disease in carbohydrate metabolism disorders.
Full Text
##article.viewOnOriginalSite##References
- American Diabetes Association Professional Practice Committee; 6. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes–2024. Diabetes Care. 2024;47(Suppl._1):S111-25. doi: 10.2337/dc24-S006
- Karasik A, Lanzinger S, Chia-Hui Tan E, et al. Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study. Diabetes Metab. 2023;49:101418.
- Cesta CE, Rotem R, Bateman BT, et al. Safety of GLP-1 Receptor Agonists and Other Second-Line Antidiabetics in Early Pregnancy. JAMA Intern Med. 2024;184(2):144-52. doi: 10.1001/jamainternmed.2023.6663
- Ametov AS, Gusenbekova DG. Influence of IDPP-4 on Fat Metabolism in Patients with Type 2 Diabetes. Int J Clin Experiment Med Sci. 2019;4(6):78-86. doi: 10.11648/j.ijcems.20180406.11
- Matthews DR, Paldánius PM, Proot P, et al. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. Lancet. 2019; 394(10208):1519-29. doi: 10.1016/S0140-6736(19)32131-2
- Дедов И.И., Шестакова М.В., Майоров А.Ю., и др. Сахарный диабет 2 типа у взрослых. Сахарный диабет. 2020;23(2S):4-102 [Dedov II, Shestakova MV, Mayorov AY, et al. Diabetes mellitus type 2 in adults. Diabetes Mellitus. 2020;23(2S):4-102 (in Russian)]. doi: 10.14341/DM12507
- Raz I, Mosenzon O, Bonaca MP, et al. DECLARE-TIMI 58: Participants’ baseline characteristics. Diabetes Obes Metab. 2018;20(5):1102-10. doi: 10.1111/dom.13217
- Ku EJ, Jung KY, Kim YJ, et al. Four-Year Durability of Initial Combination Therapy with Sitagliptin and Metformin in Patients with Type 2 Diabetes in Clinical Practice; COSMIC Study. PLoS One. 2015;10(6):e0129477. doi: 10.1371/journal.pone.0129477
- Brar G, Tsukamoto H. Alcoholic and non-alcoholic steatohepatitis: global perspective and emerging science. J Gastroenterol. 2019;54:21-5. doi: 10.1007/s00535-018-01542-w
- Nadinskaia M, Maevskaya M, Ivashkin V, et al. Ursodeoxycholic acid as a means of preventing atherosclerosis, steatosis and liver fibrosis in patients with nonalcoholic fatty liver disease. World J Gastroenterol. 2021;27(10):959-75. doi: 10.3748/wjg. v27.i10.959
